In parallel, STING agonists have the potential to induce the expression of inhibitory molecules, such as programmed death-ligand 1 (PD-L1) and indoleamine 2, 3-dioxygenase 1 (IDO1), which counteract the tumor-suppressive effects2,20. This evidence concerns the gene IDO1 and neoplasm.